ÂÜÀòÂÒÂ×

Always driven to improve patients’ lives, Jan Adams has built up more than 15 years of experience in healthcare and biopharmaceuticals.

Jan significantly contributed to working out our concise therapeutic area strategy and led the design and implementation of a future-proof R&D operating model that can successfully execute our strategy – flexible and modality-agnostic while leveraging a strong global network.

Jan joined Grünenthal in July 2017 as Head Corporate Strategy and Portfolio Management, working at the interface between strategy, research, development and commercial. Prior to joining Grünenthal, he served in roles with increasing levels of responsibility at Novartis and Takeda, as well as within McKinsey & Company’s global Pharmaceutical and Medical Products practice.